Home › B-Cell Lymphoma › Maryland
B-Cell Lymphoma clinical trials in Maryland
7 studies for B-Cell Lymphoma are looking for participants at sites in Maryland.
Cities in Maryland
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 3 to 39 · All sexes · Updated Sep 30, 2026 · NCT05442515A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- The University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06742996Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
- Walter Reed National Military Medical Center, Bethesda
RecruitingObservational study
Ages 4 and older · All sexes · Updated Sep 3, 2026 · NCT07652580Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Aug 25, 2026 · NCT05389423A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- American Oncology Partners of Maryland, PA, Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05254743DALY II USA/ MB-CART2019.1 for DLBCL
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Johns Hopkins University, Baltimore
- National Cancer Institute, Pediatric Oncology Branch, Bethesda
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.